EGFR and non-small cell lung carcinoma: As we showed herein (Tables 1 and 2), LASSBio‐1974 (2) has demonstrated lack of selectivity against different NSCLC cell lines harboring distinct EGFR mutations, high apoptotic‐inducing potential comparable to CA‐4 (Figure 3), and distinct cell cycle modulation according to the concentration (Figure 5).